Clinical Trial Update: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating SBRT with sintilimab and GM-CSF for advanced non-small cell lung cancer (Stage IV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• SBRT (stereotactic body radiotherapy)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: NSCLC Stage IV | Phase 2 | Status: UNKNOWN